Samuel “Bo” Bartholomew

Samuel “Bo” Bartholomew is CEO of EvidenceCare and Managing Partner of Rockmont Investments. Bo leads EvidenceCare’s effort to empower better care decisions within the EHR so that every clinical decision will provide the right care at the right time. He also serves on the board of ProviderTrust and Mindera Health with the goal of bringing healthcare’s next generation of technology to the forefront.

Prior to EvidenceCare, Bo was CEO and founder of PharmMD (now AdhereHealth), a technology leader in medication therapy management services. He served as chief revenue officer at Shearwater Health and has been a board member of numerous health tech ventures over the years. Bo also incubated a health advocacy company and a telemedicine physician access start-up company. He spent four years with HCA’s Executive Development program, where he helped build one of HCA’s newest hospitals and then managed HCA’s oldest hospital.

Bo chairs the Board of the Nashville Fellows Program focused on training the next generation of leaders and is passionate about equipping future leaders to impact our world for good. Bo earned his MBA from Vanderbilt’s Owen School of Management and has a Masters in Christian Studies from Regent College in Vancouver, BC and his undergraduate from Davidson College in North Carolina.

Ron Rocca

Mr. Rocca brings over two decades of biotech and diagnostics industry experience, including eleven years of developing and commercializing diagnostic products for autoimmune-related diseases. His prior role was President and CEO of Exagen Inc. (NASDAQ: XGN) which commercialized a suite of testing products enabling healthcare providers to improve care for patients through the differential diagnosis, prognosis and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Prior to Exagen, Mr. Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus Laboratories, Inc., a specialty pharmaceutical and diagnostic company focused on diseases in gastroenterology and oncology. He helped grow the company’s sales to $200 million-plus annually before playing an instrumental role in the $1.4 billion acquisition by Nestlé Health Science S.A. in 2011. Prior to Prometheus, Mr. Rocca was the General Manager of Alpharma Inc., a specialty pharmaceutical company. Earlier in his career, Mr. Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company. Mr. Rocca received a B.A. in Marketing and Personnel Management from Towson University.

Deborah L. Rice-Johnson

Ms. Rice-Johnson has more than 30 years of experience in the health insurance industry and is CEO of Diversified Businesses for Highmark Inc. and chief growth officer. Her leadership has not only redefined the payer-provider relationship and yielded unparalleled financial performance, but she has also delivered innovative clinical solutions that aim to improve health outcomes. Her Board affiliations include Blue Health Intelligence, Penn State Health, Dollar Bank, Evio, Carlow University, United Way of Southwestern Pennsylvania, Epilepsy Association of Western and Central Pennsylvania, Pittsburg Penguins Foundation, and Variety the Children’s Charity.

Ms. Rice-Johnson holds a bachelor’s degree in business management from Carlow University.

Andrew Offer

Andrew Offer has been a member of the MiNDERA Board of Directors since 2015. He is a General Partner and the Chief Executive Officer of Scientific Health Development. With over 15 years of healthcare investment experience, Mr. Offer serves on the board of directors for most active SHD portfolio companies including Sight Sciences (Nasdaq: SGHT), in addition to historically acting in the capacity of Chief Financial Officer for multiple portfolio companies. Prior to joining SHD, he spent more than 3 years at VMG Health, where he excelled in business valuation exclusively in the healthcare industry. Mr. Offer graduated Magna Cum Laude with multiple honors distinctions earning a B.B.A. in Finance from Texas A&M University. In addition, Mr. Offer earned the Chartered Financial Analyst (CFA) designation in 2009 and is a member of the CFA Institute and the CFA Society of Dallas-Fort Worth.

Joseph Cook, III

Joseph Cook III has served as a member of our board of directors since August 2019. Since February 2003, Mr. Cook has served as a Managing Director at Mountain Group Partners, an investment firm with investments in the Life Sciences, AgTech and Technology sectors. From January 2001 until February 2003, Mr. Cook served as a Director, Private Placements in the Investment Banking Group of Robert W. Baird & Co. Incorporated. Mr. Cook also previously served as a Vice President in the Investment Banking Group at J.C. Bradford & Co. Mr. Cook serves on the board of directors of Castle Biosciences (NASDAQ:CSTL), a dermatologic cancer diagnostic company, and Cerebrotech Medical Systems, Inc., a machine learning cerebral diagnostic company. Mr. Cook holds a B.A. degree in Economics from Davidson College.

Tahir Mahmood, PhD

Tahir Mahmood is co-founder of Mindera Health and co-invented and developed the company’s core technology platform. He is Chief Executive Officer and Co-founder at Applied Molecular Transport (NASDAQ: AMTI), a clinical stage biotech developing oral targeted biological therapeutics for treating immune-mediated inflammation, metabolic and other diseases. Previously, Tahir was a leader in the US West Coast Life Sciences practice at the management consulting firm Booz Allen Hamilton and was Managing Director at Lake Sherwood Partners. He was Visiting Investigator in the Department of Chemistry and Worm Institute for Research and Medicine at The Scripps Research Institute in La Jolla, CA and was previously Principal Business Analyst at Amgen, supporting R&D, and BD, M&A and strategic corporate venture fund transactions. Earlier, he was at Chienna (acquired by OctoPlus) and IsoTis S.A. (acquired by Integra Life Sciences). 

Tahir has authored peer-reviewed publications and is inventor on issued and pending patents. He received a BASc in Mechanical Engineering and MSc in Biomedical Engineering from the University of Toronto, and holds a PhD in Chemical & Biomedical Engineering from a collaborative program between the University of Twente (The Netherlands) and MIT at the Harvard-MIT Division of Health Sciences and Technology and Children’s Hospital Boston.